GLMD
Galmed·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 0
Stock Price Surged Significantly
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About GLMD
Galmed Pharmaceuticals Ltd.
A clinical-stage biopharmaceutical company that focused on liver, metabolic, fibrosis and inflammatory diseases
16 Abba Hillel Road, Ramat Gan, Israel 5250608
--
Galmed Pharmaceuticals Ltd., established in Israel on July 31, 2013, is an Israeli private company. The Company is a clinical biopharmaceutical company focused on developing and commercializing a novel, once-daily, orally available drug for the treatment of liver disease and cholesterol firmness.
Company Financials
EPS
GLMD has released its 2025 Q3 earnings. EPS was reported at -0.33, versus the expected -0.54, beating expectations. The chart below visualizes how GLMD has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
